• TAK-242 Workflows for TLR4 Inflammation Studies

  2026-08-11

  Build cleaner LPS challenge assays, neuroinflammation studies, and immune-oncology controls with TAK-242 (Resatorvid). This workflow-focused guide shows how to separate ligand-specific biology from technical failure while using selective TLR4 signaling pathway modulation.

• Phosphatase Inhibitor Cocktail 1 for CD59 Signaling

  2026-08-10

  Learn how Phosphatase Inhibitor Cocktail 1 supports phosphorylation-state preservation when studying the CD59–JAK2–STAT3 axis in pancreatic cancer. This assay-focused guide explains component coverage, workflow decisions, controls, and limitations beyond generic phosphoproteomics guidance.

• Capsaicin Workflows for TRPV1 and KDM1A Research

  2026-08-09

  Capsaicin, also called (E)-Capsaicin, connects rapid TRPV1 ion channel activation with reversible KDM1A/LSD1 inhibition. This guide turns that dual biology into practical workflows for sensory-neuron, inflammation, and gastric-cancer studies, with formulation controls and troubleshooting steps for reproducible results.

• 2'3'-cGAMP Beyond STING: A Translational Playbook

  2026-08-08

  2'3'-cGAMP is widely used as a direct STING activator, but emerging evidence suggests that its biology extends beyond canonical type I interferon signaling. This thought-leadership guide shows how translational researchers can use 2'3'-cGAMP (sodium salt) to separate STING-dependent effects from broader cGAMP biology, design more discriminating experiments, and build stronger hypotheses for immunotherapy research, cancer biology, inflammation, and antiviral studies.

• Proteoform-Specific Drug Targeting in Native Membranes

  2026-08-07

  Lutomski and colleagues developed a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retinal disc membranes, preserving proteoform-specific interaction information. The study shows how lipid modifications and proteoform identity influence G-protein assembly and the off-target binding of PDE5 inhibitors to retinal PDE6, providing a framework for more precise drug-discovery studies.

• Nonivamide: TRPV1 Agonism for Translational Oncology and Neu

  2026-08-07

  Nonivamide, a capsaicin analog and selective TRPV1 agonist, is reshaping strategies in cancer and neuroimmune translational research. This article elucidates its mechanistic pathways—including mitochondrial apoptosis and reactive oxygen species modulation—and translates these findings into actionable guidance for in vitro, in vivo, and disease model applications. By integrating new evidence on TRPV1's role in sensory neuron cross-talk and allokinesis, we map a path for next-generation protocol optimization and cross-domain insight beyond conventional product literature.

• Cleavage-Resistant TREM2 Enhances Macrophage Efferocytosis i

  2026-08-06

  Dong et al. engineered a synthetic, cleavage-resistant TREM2 receptor (CRT) that amplifies macrophage efferocytosis and mitigates inflammation by resisting ADAM17-mediated shedding. Their innovative use of phosphatidylserine-functionalized lipid nanoparticles for selective mRNA delivery offers a promising therapeutic strategy for diseases associated with defective apoptotic cell clearance.

• Tetrandrine Alkaloid: Applied Protocols for Ion Channel Rese

  2026-08-06

  Tetrandrine alkaloid stands out for its robust DMSO solubility and reproducibility in ion channel modulation and inflammation studies. This article details practical workflows, troubleshooting strategies, and advanced applications that empower researchers in neuroscience, cancer biology, and beyond.

• AMG 9810: Advanced TRPV1 Antagonist Workflows in Pain Resear

  2026-08-05

  Unlock the full potential of AMG 9810 as a nanomolar-potency TRPV1 antagonist for dissecting pain and metabolic stress signaling. This guide delivers practical workflows, troubleshooting strategies, and unique translational insights—bridging cellular signaling with real-world assay optimization.

• Ordered DNA Nanostructures Advance Enzymatic DNA Synthesis

  2026-08-05

  A new study introduces a tetrahedral DNA nanostructure interface that significantly improves the efficiency and accuracy of enzymatic oligonucleotide synthesis (EOS). By enhancing enzyme accessibility and reducing synthesis errors, this approach supports high-fidelity DNA assembly, enabling advances in DNA storage and synthetic biology.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-08-04

  0.4% Trypan Blue Solution enables rapid, visual discrimination of live and dead cells, supporting accurate viability measurements in cell culture and cytotoxicity workflows. It is intended for research-only uses and should not be applied in diagnostic or clinical settings.

• D-N-Acetylgalactosamine: Technical Use in Glycoprotein Analy

  2026-08-04

  D-N-Acetylgalactosamine addresses the need for a high-purity, water-soluble standard in the analysis of glycoprotein constituents, especially within neurological research and brain heteropolysaccharide studies. It should not be used in protocols that require ethanol solubility or long-term storage of working solutions, ensuring that researchers follow precise handling and workflow parameters for reproducible results.

• Dissecting N-Type Ca Channel Blockade by Spider Toxin v-Agat

  2026-08-03

  Sidach and Mintz (2000) redefined the pharmacological profiling of neuronal high-threshold calcium channels using v-agatoxin-IVA, clarifying its selectivity and revealing the complexity of channel subtypes in mammalian neurons. Their findings have direct implications for experimental approaches probing calcium-dependent signaling, secretion, and channel subtype classification.

• GSK J4 HCl: Advancing JMJD3 Inhibition in Inflammatory and P

  2026-08-03

  Explore how GSK J4 HCl, a potent JMJD3 inhibitor, enables researchers to dissect histone methylation dynamics in inflammation and pregnancy immunity. This article delivers distinct insights into assay design, translational relevance, and protocol optimization.

• AP-2α Suppresses MGMT to Reverse TMZ Resistance in Recurrent

  2026-08-02

  This study demonstrates that transcription factor AP-2α directly downregulates MGMT expression, sensitizing recurrent glioblastoma (GBM) cells to temozolomide (TMZ) by enhancing DNA damage. These findings clarify the transcriptional control underlying MGMT-mediated chemoresistance and point to new strategies for overcoming therapeutic resistance in aggressive brain tumors.

14802 records 1/987 page Next 12345 下5页 Last page